In preclinical models of NASH, genetic deletion or pharmacological inhibition of ASK1 reduces p38 and JNK phosphorylation, resulting in reduced hepatic steatosis, inflammation, and fibrosis [135]. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.